Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 11:06 AM ET
Protagonist Therapeutics Inc (PTGX) Earnings: Report Dates and Results
Protagonist Therapeutics (PTGX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Protagonist Therapeutics reported EPS of $3.07, above the $2.58 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PTGX has an expected report date of Feb 23, 2027.
Earnings History
Of the 39 quarters below that had an estimate, PTGX beat 20, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $274.41M, up 5726.1% from $4.71M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.07 | $2.58 | $0.13 - $3.40 | +18.99% | Beat | N/A | 12 | 2 up, 2 down | Nov 5, 2026 | $274.41M |
| Jun 30, 2026 | $2.29 | $2.11 | $0.09 - $2.79 | +8.53% | Beat | N/A | 10 | N/A | Aug 5, 2026 | $213.47M |
| Mar 31, 2026 | $0.05 | -$0.65 | -$1.23 - -$0.25 | +107.69% | Beat | N/A | 7 | 2 up, 3 down | May 5, 2026 | $56.37M |
| Dec 31, 2025 | -$0.69 | -$0.34 | -$0.73 - $0.09 | -102.76% | Miss | -134.8% | 9 | 1 up, 1 down | Feb 25, 2026 | $7.44M |
| Sep 30, 2025 | -$0.62 | -$0.64 | -$0.79 - -$0.57 | +3.13% | Beat | N/A | 9 | 1 up, 1 down | Nov 6, 2025 | $4.71M |
| Jun 30, 2025 | -$0.55 | -$0.52 | -$0.73 - -$0.09 | -5.77% | Miss | N/A | 9 | 3 up, 4 down | Aug 6, 2025 | $5.55M |
| Mar 31, 2025 | -$0.19 | $0.11 | -$0.58 - $1.87 | -272.73% | Miss | -105.8% | 8 | 1 up, 0 down | May 6, 2025 | $28.32M |
| Dec 31, 2024 | $1.98 | $0.25 | -$0.64 - $1.73 | +692.00% | Beat | +350.0% | 7 | 1 up, 0 down | Feb 21, 2025 | $170.64M |
| Sep 30, 2024 | -$0.54 | -$0.53 | -$0.71 - -$0.45 | -1.89% | Miss | N/A | 8 | 0 up, 0 down | Nov 7, 2024 | $4.67M |
| Jun 30, 2024 | -$0.50 | -$0.41 | -$0.81 - $0.05 | -21.95% | Miss | N/A | 6 | 0 up, 0 down | Aug 6, 2024 | $4.17M |
| Mar 31, 2024 | $3.26 | $1.60 | -$0.62 - $3.95 | +103.75% | Beat | N/A | 5 | 0 up, 0 down | May 7, 2024 | $254.95M |
| Dec 31, 2023 | $0.44 | -$0.03 | -$0.66 - $0.44 | N/A | N/A | N/A | 5 | 0 up, 0 down | Feb 27, 2024 | $60.00M |
| Sep 30, 2023 | -$0.58 | -$0.70 | -$0.76 - -$0.67 | +17.14% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.68 | -$0.66 | -$0.70 - -$0.60 | -3.03% | Miss | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.67 | -$0.70 | -$0.91 - -$0.56 | +4.29% | Beat | N/A | 6 | 1 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.69 | -$0.64 | -$0.82 - -$0.34 | -7.81% | Miss | N/A | 6 | 1 up, 1 down | Mar 15, 2023 | N/A |
| Sep 30, 2022 | -$0.64 | -$0.85 | -$1.05 - -$0.76 | +24.71% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2022 | N/A |
| Jun 30, 2022 | -$0.84 | -$0.98 | -$1.05 - -$0.66 | +14.29% | Beat | N/A | 6 | 0 up, 0 down | Aug 4, 2022 | $859000 |
| Mar 31, 2022 | -$0.43 | -$0.60 | -$1.03 - -$0.43 | +28.33% | Beat | N/A | 6 | 0 up, 0 down | May 4, 2022 | $25.72M |
| Dec 31, 2021 | -$0.77 | -$0.78 | -$0.97 - -$0.60 | +1.28% | Beat | N/A | 8 | 0 up, 0 down | Feb 28, 2022 | $8.62M |
| Sep 30, 2021 | -$0.70 | -$0.66 | -$0.77 - -$0.57 | -6.06% | Miss | N/A | 7 | N/A | Nov 3, 2021 | $10.29M |
| Jun 30, 2021 | -$0.69 | -$0.53 | -$0.69 - -$0.10 | -30.19% | Miss | N/A | 7 | N/A | Aug 4, 2021 | $2.27M |
| Mar 31, 2021 | -$0.54 | -$0.56 | -$0.62 - -$0.45 | +3.57% | Beat | N/A | 5 | N/A | May 4, 2021 | $6.19M |
| Dec 31, 2020 | -$0.48 | -$0.48 | -$0.54 - -$0.42 | 0.00% | In line | N/A | 5 | N/A | Mar 10, 2021 | $5.65M |
| Sep 30, 2020 | -$0.21 | -$0.56 | -$0.70 - -$0.56 | +62.50% | Beat | N/A | 4 | N/A | Nov 4, 2020 | $13.11M |
| Jun 30, 2020 | -$0.57 | -$0.58 | -$0.66 - -$0.54 | +1.72% | Beat | N/A | 4 | N/A | Aug 6, 2020 | $6.22M |
| Mar 31, 2020 | -$0.72 | -$0.69 | -$0.77 - -$0.57 | -4.35% | Miss | N/A | 5 | N/A | May 7, 2020 | $3.65M |
| Dec 31, 2019 | -$0.63 | -$0.70 | -$0.86 - -$0.48 | +10.00% | Beat | N/A | 4 | N/A | Mar 10, 2020 | $2.72M |
| Sep 30, 2019 | -$0.61 | -$0.73 | -$0.84 - -$0.51 | +16.44% | Beat | N/A | 5 | N/A | Nov 6, 2019 | $4.14M |
| Jun 30, 2019 | -$1.18 | -$0.27 | -$0.65 - $0.28 | -337.04% | Miss | N/A | 6 | N/A | Aug 7, 2019 | N/A |
| Mar 31, 2019 | -$0.58 | -$0.59 | -$0.71 - -$0.44 | +1.69% | Beat | N/A | 5 | N/A | May 8, 2019 | $1.56M |
| Dec 31, 2018 | -$0.57 | -$0.47 | -$0.67 - -$0.17 | -21.28% | Miss | N/A | 5 | N/A | Mar 12, 2019 | $2.35M |
| Sep 30, 2018 | -$0.38 | -$0.33 | -$0.69 - -$0.11 | -15.15% | Miss | N/A | 3 | N/A | Nov 6, 2018 | $6.12M |
| Jun 30, 2018 | -$0.41 | -$0.29 | -$0.51 - -$0.09 | -41.38% | Miss | N/A | 3 | N/A | Aug 7, 2018 | $11.67M |
| Mar 31, 2018 | -$0.36 | -$0.24 | -$0.39 - -$0.13 | -50.00% | Miss | N/A | 3 | N/A | May 9, 2018 | $10.78M |
| Dec 31, 2017 | -$0.15 | -$0.35 | -$0.42 - -$0.27 | +57.14% | Beat | N/A | 5 | N/A | Mar 7, 2018 | $11.28M |
| Sep 30, 2017 | -$0.29 | -$0.61 | N/A | +52.46% | Beat | N/A | N/A | N/A | Nov 6, 2017 | $8.78M |
| Jun 30, 2017 | -$0.89 | -$0.81 | N/A | -9.88% | Miss | N/A | N/A | N/A | Aug 8, 2017 | N/A |
| Mar 31, 2017 | -$0.84 | -$0.59 | N/A | -42.37% | Miss | N/A | N/A | N/A | May 10, 2017 | N/A |
| Dec 31, 2016 | -$0.67 | -$0.52 | N/A | -28.85% | Miss | N/A | N/A | N/A | Mar 7, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after $4.20 the year before. It was -$20.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.05 | -148.8% |
| Dec 31, 2024 | $4.20 | N/A |
| Dec 31, 2023 | -$1.49 | N/A |
| Dec 31, 2022 | -$2.60 | N/A |
| Dec 31, 2021 | -$2.70 | N/A |
| Dec 31, 2020 | -$1.98 | N/A |
| Dec 31, 2019 | -$3.00 | N/A |
| Dec 31, 2018 | -$1.72 | N/A |
| Dec 31, 2017 | -$2.17 | N/A |
| Dec 31, 2016 | -$20.61 | N/A |
Frequently Asked Questions About PTGX
When is Protagonist Therapeutics's next earnings date?
Protagonist Therapeutics's next earnings report is expected for Feb 23, 2027.
Did PTGX beat earnings estimates last quarter?
Yes. Protagonist Therapeutics reported EPS of $3.07 for the quarter ended Sep 30, 2026, above the $2.58 estimate, a 18.99% surprise.
What EPS do analysts expect from PTGX next quarter?
The consensus EPS estimate for Protagonist Therapeutics for the quarter ending Dec 31, 2026 is -$0.46 from 16 analysts, with estimates from -$0.83 to $0.65.
How often does PTGX beat earnings estimates?
Protagonist Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +56.14%.
PTGX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors